Paper37653142
Clinical and translational advances in ovarian cancer therapy.
Konstantinopoulos PA and 1 other. Nat Cancer, 2023. Cited by 356 papers, by iCite.
Cite this record
ConductScience Library. Clinical and translational advances in ovarian cancer therapy. Papers, record 37653142. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37653142
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Review, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ovarian Neoplasms | Major topic |
| Humans | |
| Female | |
| Carcinoma, Ovarian Epithelial | |
| Platinum |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA006516 | NCI NIH HHS | United States | P30CA006516 | PubMed and NIH | NIH RePORTER |
| R01 CA258553 | NCI NIH HHS | United States | R01CA258553 | PubMed and NIH | NIH RePORTER |
| P50CA240243 | NIH | NIH RePORTER |
References157
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 2 | 35090748 | European cancer mortality predictions for the year 2022 with focus on ovarian cancer. | Ann Oncol | 2022 | https://conductscience.org/library/papers/35090748 | PubMed |
| 3 | 35020204 | Cancer statistics, 2022. | CA Cancer J Clin | 2022 | https://conductscience.org/library/papers/35020204 | PubMed |
| 4 | 35606067 | The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. | Gynecol Oncol | 2022 | https://conductscience.org/library/papers/35606067 | PubMed |
| 5 | 33020491 | Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome. | Nat Commun | 2020 | https://conductscience.org/library/papers/33020491 | PubMed |
| 6 | 20826764 | Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. | Science | 2010 | https://conductscience.org/library/papers/20826764 | PubMed |
| 7 | 26463832 | Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. | Cancer Discov | 2015 | https://conductscience.org/library/papers/26463832 | PubMed |
| 8 | 30917260 | Mucinous Ovarian Carcinoma. | N Engl J Med | 2019 | https://conductscience.org/library/papers/30917260 | PubMed |
| 9 | 31335355 | p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis. | Am J Surg Pathol | 2019 | https://conductscience.org/library/papers/31335355 | PubMed |
| 10 | 26720728 | Inherited Mutations in Women With Ovarian Carcinoma. | JAMA Oncol | 2016 | https://conductscience.org/library/papers/26720728 | PubMed |
| 11 | 36075393 | NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022. | J Natl Compr Canc Netw | 2022 | https://conductscience.org/library/papers/36075393 | PubMed |
| 12 | 31986064 | Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. | J Clin Oncol | 2020 | https://conductscience.org/library/papers/31986064 | PubMed |
| 13 | 35715633 | Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma. | Br J Cancer | 2022 | https://conductscience.org/library/papers/35715633 | PubMed |
| 14 | 31672974 | Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. | Nat Commun | 2019 | https://conductscience.org/library/papers/31672974 | PubMed |
| 15 | 22343227 | Symptoms associated with ovarian cancer. | Clin Obstet Gynecol | 2012 | https://conductscience.org/library/papers/22343227 | PubMed |
| 16 | 24219974 | Staging classification for cancer of the ovary, fallopian tube, and peritoneum. | Int J Gynaecol Obstet | 2014 | https://conductscience.org/library/papers/24219974 | PubMed |
| 17 | 34328210 | Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. | Cochrane Database Syst Rev | 2021 | https://conductscience.org/library/papers/34328210 | PubMed |
| 18 | 20833283 | Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists? | Gynecol Oncol | 2010 | https://conductscience.org/library/papers/20833283 | PubMed |
| 19 | 27502591 | Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27502591 | PubMed |
| 20 | 35690073 | Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. | Lancet Oncol | 2022 | https://conductscience.org/library/papers/35690073 | PubMed |
Cited by276
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 356 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42985462 | Ovarian Carcinoma: Signal Pathways and Clinical Studies. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42985462 | PubMed |
| 42968661 | Ferroportin deficiency drives olaparib resistance in ovarian cancer via the cGAS-STING-STAT3 survival axis. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/42968661 | PubMed |
| 42965079 | Near-Infrared Light-Responsive Liposomes for Modulating Switchable CAR-T Cell Therapy. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42965079 | PubMed |
| 42959417 | The dual role of autophagy in gynecologic malignancies: promoting and inhibiting. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42959417 | PubMed |
| 42922966 | Differential sparse attention framework for accurate ovarian cancer subtype classification using DenseNet121. | Front Digit Health | 2026 | https://conductscience.org/library/papers/42922966 | PubMed |
| 42909065 | Plasticity and immune marker profiling of tumour- and ascites-derived microtumours in serous ovarian cancer: relevance for short-term culture models. | Front Immunol | 2026 | https://conductscience.org/library/papers/42909065 | PubMed |
| 42883230 | Phytochemical Profiles and Anticancer Activity of the Three Prosopis Species Growing in Qatar Against Lung and Ovarian Cancer Cells. | Molecules | 2026 | https://conductscience.org/library/papers/42883230 | PubMed |
| 42870871 | Glaucocalyxin A sensitizes ovarian cancer cells to PARP inhibitors by inducing DNA damage. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42870871 | PubMed |
| 42850290 | HAMNO and CGK733 as BRCAness-driven candidates exhibit synthetic lethality with olaparib in BRCA-proficient ovarian cancer. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42850290 | PubMed |
| 42844251 | CYBRD1 is transcriptionally regulated by RUNX1 and mediates JAK2/STAT3 signaling activation during ovarian cancer progression. | Oncogenesis | 2026 | https://conductscience.org/library/papers/42844251 | PubMed |
| 42789557 | BCAM-AKT2 fusion protein promotes unfolded protein response driven oncogenic signaling in SKOV3 epithelial ovarian cancer cell line. | PLoS One | 2026 | https://conductscience.org/library/papers/42789557 | PubMed |
| 42769152 | Ovarian cancer proteomic landscape changes across different pathological stages and biomarker-sets identified with integrative multiomics analysis. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42769152 | PubMed |
| 42753071 | Natural killer cells in ovarian cancer therapy: mechanisms, evasion, and therapeutic innovations. | Inflammopharmacology | 2026 | https://conductscience.org/library/papers/42753071 | PubMed |
| 42729152 | Integrative network toxicology and molecular docking reveal epigenetic and endocrine-disrupting mechanisms of PFAS in ovarian cancer. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42729152 | PubMed |
| 42650243 | Novel Exploratory Transcriptomic Candidates as Biomarkers and Cancer Hallmark Fingerprints for Ovarian Endometroid and Clear Cell Carcinomas in Women. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/42650243 | PubMed |
| 42630491 | Ovarian Cancer Stem Cells: Mechanisms of Progression and Therapeutic Strategies. | Oncol Res | 2026 | https://conductscience.org/library/papers/42630491 | PubMed |
| 42609197 | Rising Ovarian Cancer Burden in Africa, 2009-2023: Epidemiological Change, Age-Specific Patterns, COVID-19-Related Deviations, and Future Forecasts. | Int J Womens Health | 2026 | https://conductscience.org/library/papers/42609197 | PubMed |
| 42601376 | The phosphoproteome of ovarian carcinoma delineates signaling signatures and potentially druggable targets across histotype stages. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42601376 | PubMed |
| 42541248 | Aberrant sialylation in cancer: From molecular mechanisms to potential therapeutics. | Genes Dis | 2026 | https://conductscience.org/library/papers/42541248 | PubMed |
| 42532631 | Cancer-associated mesothelial cells drive immune escape and therapy resistance in ovarian cancer. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42532631 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37653142
GET https://conductscience.org/api/papers/v1/37653142/references?page=2